Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation

ISSN: 1875-6557 (Online)
ISSN: 1573-403X (Print)


Volume 10, 4 Issues, 2014


Download PDF Flyer




Current Cardiology Reviews

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Fei Lu
University of Minnesota Medical School
Minneapolis, MN 55455
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation

Author(s): Jonathan L. Halperin and Paul Dorian

Affiliation: Cardiovascular Institute, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029-6574, USA.

Abstract

Patients with non-valvular atrial fibrillation (AF) face an increased risk of stroke compared with those in normal sinus rhythm. The vitamin K antagonist warfarin, available for over half a century, is highly effective in reducing the risk of stroke in patients with AF, but it is a difficult drug to use properly. As a result, it is challenging to keep the anticoagulant effect of warfarin in the desired range. Newer oral anticoagulants (NOACs) that directly inhibit Factor IIa (thrombin) or Factor Xa provide reliable anticoagulation when administer in fixed oral doses without routine coagulation monitoring. This manuscript will review in detail the pivotal trials of these NOACs that led to their approval as well as comment on the factors that should influence their selection.

Keywords: Anticoagulation, antithrombotic therapy, atrial fibrillation, factor IIa inhibitors, factor Xa inhibitors, stroke, thrombin, thromboembolism.

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 10
Issue Number: 4
First Page: 297
Last Page: 302
Page Count: 6
DOI: 10.2174/1573403X10666140513104523
Advertisement

Related Journals



Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science